Prometheon is replacing needle injections with once weekly patches. Our patented transdermal platform technology for passive delivery of large molecule drugs such as insulin or small chemical drugs such as cyclosporin A will increase access to health care worldwide, grow existing markets, and create new prevention markets. Our products under development are designed to be simple-to-use and convenient for patients and their providers. Our corporate culture offers innovative business development tools and investment models for industry partners and investors.
Our needle-free products such as our flagship insulin TruePatch™ currently under development, focus on patient convenience. Simple solutions make it easier to receive the full benefit of therapy through increased compliance that will ensure that you achieve your maximum health potential. Our products are temperature-stable, allowing for greater access to treatment worldwide. We seek to create socially responsible products for you, your families, and your communities.
Our patented needle-free transdermal patch platform technology is attractive for life cycle management and market differentiation of generics and promising new pipeline therapies. To date, we have delivered a peptide drug as large as growth hormone (22 kDa). Our de-risked partnership model begins with stringent in vitro testing to characterize permeation rate, dose range, and safety of candidate drug(s) of any class in 2-3 months. We can test over 100 drugs simultaneously,
Our investors enjoy a unique situation, with multiple product lines and revenue streams mitigating risk and creating a positive feedback loop that protects equity and encourages follow-on investment. Our flagship once weekly needle-free basal insulin TruePatch™ is expected to not only increase access (grow market), but also to enable implementation of early insulin therapy for those with prediabetes (i.e impaired fasting glucose) who are at high risk of developing type 2 diabetes (create new prevention market).